Johnson & Johnson (NYSE:JNJ) is included among the many 15 Dividend Shares that Outperform the S&P 500.
Barclays lifted its value target on Johnson & Johnson (NYSE:JNJ) to $197 from $176 on December 2 whereas sustaining an Equal Weight score. The firm also refreshed its estimates for the company.
Johnson & Johnson (NYSE:JNJ) continues to benefit from a powerful balance sheet, a discoveredation that has long supported consistent stability and allowed the firm to make substantial investments in analysis and development in addition to targeted acquisitions. Its newest move was the acquisition of Halda Therapeutics in a $3.05 billion deal aimed at increasing its oncology pipeline. The acquisition gives J&J access to Halda’s platkind for developing oral most cancers treatments, aligning with its broader give attention to cutting-edge therapeutics.
Johnson & Johnson (NYSE:JNJ) stays strategically centered on high-margin, innovation-driven classes inside its Progressive Medicine unit, together with oncology, immunology, and neuroscience. Its MedTech arm is concentrated on faster-growing markets such as surgical robotics and digital surgical procedure. For the third quarter, J&J posted web gross sales of $24 billion, a year-over-year enhance of 6.8%, whereas web earnings surged 91% to $5.2 billion.
Johnson & Johnson (NYSE:JNJ) is a world healthcare company working across two core segments: Progressive Drugs and MedTech.
Whereas we acknowledge the potential of JNJ as an funding, we imagine sure AI shares supply larger upside potential and carry much less draw back threat. In the event you’re searching for an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the finest short-term AI inventory.
READ NEXT: 15 Excessive High quality Dividend Shares for Lengthy-Time period Buyers and 14 Greatest Up and Coming Dividend Shares to Purchase.
Disclosure: None.